Novem Group Purchases 9,205 Shares of Merck & Co., Inc. $MRK

Key Points

• Novem Group increased its stake in Merck by 23.1%, buying 9,205 shares to hold 48,989 shares worth about $5.16 million per its latest Form 13F filing.
• Merck faces mixed news on its pipeline: the FDA granted priority review for KEYTRUDA combinations and the EU approved ENFLONSIA for infant RSV prophylaxis, but the Phase 3 LITESPARK‑012 trial failed to meet key primary endpoints, a material setback under review by management.
• Corporate insiders have been net sellers, disposing of 320,176 shares worth roughly $38.28 million over the past 90 days (including large sales by the CMO and EVP), while institutional investors still own about 76.07% of the stock.

Novem Group raised its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 23.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 48,989 shares of the company's stock after purchasing an additional 9,205 shares during the period. Novem Group's holdings in Merck & Co., Inc. were worth $5,157,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Darwin Wealth Management LLC increased its stake in Merck & Co., Inc. by 237.4% in the third quarter. Darwin Wealth Management LLC now owns 307 shares of the company's stock valued at $26,000 after purchasing an additional 216 shares in the last quarter. Barnes Dennig Private Wealth Management LLC increased its stake in Merck & Co., Inc. by 302.3% in the third quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company's stock valued at $30,000 after purchasing an additional 266 shares in the last quarter. United Financial Planning Group LLC bought a new stake in Merck & Co., Inc. in the third quarter valued at approximately $31,000. Wealth Watch Advisors INC bought a new stake in Merck & Co., Inc. in the third quarter valued at approximately $34,000. Finally, Deane Retirement Strategies Inc. bought a new stake in Merck & Co., Inc. in the third quarter valued at approximately $35,000. Institutional investors own 76.07% of the company's stock.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: FDA granted priority review for two supplemental BLAs for KEYTRUDA (and KEYTRUDA QLEX) in combination with Padcev for cisplatin-eligible muscle‑invasive bladder cancer — a regulatory acceleration that can expand KEYTRUDA’s label and near‑term revenue potential. FDA Grants Priority Review for KEYTRUDA and KEYTRUDA QLEX with Padcev
• Positive Sentiment: European Union approves ENFLONSIA (RSV monoclonal antibody) to protect infants during their first RSV season — adds a near‑term revenue driver in prophylaxis and diversifies pediatric portfolio. Merck Wins EU Approval for ENFLONSIA to Protect Infants from RSV
• Neutral Sentiment: Market commentary and valuation pieces highlight Merck’s recent outperformance (one‑year gains) and short‑term pullbacks — useful context for positioning but not new company fundamentals. 3 Reasons We Love Merck (MRK)
• Negative Sentiment: Merck and Eisai said the Phase 3 LITESPARK‑012 combination regimens for certain first‑line advanced renal cell carcinoma failed to meet key primary endpoints — a material pipeline setback for MRK’s kidney‑cancer franchise and a driver of today’s downside pressure. Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage study
• Negative Sentiment: Merck/Eisai corporate update on the Phase 3 LITESPARK‑012 trial acknowledges the miss and signals additional data review; this will prompt investor focus on secondary endpoints, label prospects, and any impact to long‑term guidance. Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial

Insider Activity at Merck & Co., Inc.

In other news, CMO Chirfi Guindo sold 20,000 shares of the stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of $121.88, for a total transaction of $2,437,600.00. Following the completion of the transaction, the chief marketing officer directly owned 80,615 shares in the company, valued at $9,825,356.20. This represents a 19.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Richard R. Deluca sold 37,685 shares of the stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $120.92, for a total transaction of $4,556,870.20. Following the transaction, the executive vice president owned 160,174 shares of the company's stock, valued at approximately $19,368,240.08. This represents a 19.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 320,176 shares of company stock worth $38,281,735. Corporate insiders own 0.09% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have commented on MRK shares. Guggenheim upped their target price on shares of Merck & Co., Inc. from $122.00 to $140.00 and gave the company a "buy" rating in a research note on Friday, February 6th. JPMorgan Chase & Co. upped their target price on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the company an "overweight" rating in a research note on Monday, April 6th. Wells Fargo & Company raised their price objective on shares of Merck & Co., Inc. from $135.00 to $150.00 and gave the stock an "overweight" rating in a report on Thursday, March 12th. UBS Group raised their price objective on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a "buy" rating in a report on Monday, April 13th. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Merck & Co., Inc. in a report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have assigned a Hold rating to the company's stock. According to MarketBeat.com, Merck & Co., Inc. currently has a consensus rating of "Moderate Buy" and a consensus price target of $128.47.

Merck & Co., Inc. Trading Down 1.6%

Shares of NYSE:MRK opened at $117.15 on Tuesday. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $125.14. The company has a quick ratio of 1.30, a current ratio of 1.54 and a debt-to-equity ratio of 0.89. The company's fifty day simple moving average is $119.11 and its 200 day simple moving average is $106.32. The firm has a market cap of $289.34 billion, a price-to-earnings ratio of 16.09, a PEG ratio of 2.39 and a beta of 0.26.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, topping analysts' consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The business had revenue of $16.40 billion for the quarter, compared to analyst estimates of $16.19 billion. During the same period last year, the business posted $1.72 earnings per share. The firm's quarterly revenue was up 5.0% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. As a group, research analysts forecast that Merck & Co., Inc. will post 4.93 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th were paid a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date was Monday, March 16th. Merck & Co., Inc.'s dividend payout ratio is currently 46.70%.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.